DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Tirasemtiv is an investigational drug.
There have been 7 clinical trials for Tirasemtiv. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Amyotrophic Lateral Sclerosis, Sclerosis, and Motor Neuron Disease. The leading clinical trial sponsors are Cytokinetics, National Institute of Neurological Disorders and Stroke (NINDS), and [disabled in preview].
There are seven US patents protecting this investigational drug and seventy-two international patents.
Recent Clinical Trials for Tirasemtiv
|A Study for Patients Who Completed VITALITY-ALS (CY 4031)||Cytokinetics||Phase 3|
|Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year||Cytokinetics||Phase 3|
|Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)||Cytokinetics||Phase 2|
Top disease conditions for Tirasemtiv
Top clinical trial sponsors for Tirasemtiv
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tirasemtiv||Start Trial||Combination ALS therapy||Cytokinetics, Inc. (South San Francisco, CA)||Start Trial|
|Tirasemtiv||Start Trial||Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use||Cytokinetics, Inc. (South San Francisco, CA)||Start Trial|
|Tirasemtiv||Start Trial||Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use||Cytokinetics, Inc. (South San Francisco, CA)||Start Trial|
|Tirasemtiv||Start Trial||Modulating skeletal muscle||Cytokinetics, Inc. (South San Francisco, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|